1) Underlying NPAT of $680m, in line with our estimate and recent guidance;
2) 4cps final dividend, in line with our estimate and recent guidance;
3) AMP has flagged increased controllable costs in FY19 of around $100m, to account for higher professional indemnity insurance, reallocation of ‘one-off’ costs to ongoing, and from cost inflation. We have been adamant for years that AMP has been shifting too much of its cost base to one-off expenses, and it has now made a more realistic adjustment as to the true underlying cost of the business;
4) Guidance for the largest division, Australian Wealth Management, to experience -8bps of margin decline during the year, which is equivalent to -8.8%, on the back of MySuper, but also back book repricing. We still see more pain on this front;
5) AMP hasn’t made any guidance suggestions relating to the Royal Commission, meaning there could still be some more paint to come, once legislation is passed;
6) Net-flows finished the year at -$4.0 billion, worse than our -$3.8 billion estimate;
7) Bank NIM falling, and guidance for it to keep falling;
8) Life Insurance sale is delayed by 3 months, now scheduled for some time around September this year; and
9) AMP Capital remains in net-outflow.
- Forums
- ASX - By Stock
- AMP
- Full year 2018 results
Full year 2018 results, page-11
Featured News
Add AMP (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.51 |
Change
-0.023(1.47%) |
Mkt cap ! $3.829B |
Open | High | Low | Value | Volume |
$1.54 | $1.54 | $1.51 | $2.435M | 1.606M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
48 | 91612 | $1.51 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.52 | 32264 | 51 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
49 | 91726 | 1.510 |
26 | 208500 | 1.505 |
30 | 195113 | 1.500 |
11 | 143647 | 1.495 |
5 | 357854 | 1.490 |
Price($) | Vol. | No. |
---|---|---|
1.515 | 32057 | 49 |
1.520 | 135996 | 30 |
1.525 | 109568 | 15 |
1.530 | 147473 | 12 |
1.535 | 88811 | 11 |
Last trade - 14.10pm 13/11/2024 (20 minute delay) ? |
Featured News
AMP (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Michael Thurn, CEO & MD
Michael Thurn
CEO & MD
SPONSORED BY The Market Online